Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes - 《American Journal of Physiology》美国生理学杂志干细胞之家



免疫细胞治疗专区	欢迎关注干细胞微信公众号

12 3 4 5 6 7 8 9 10 ... 25 下一页

返回列表

查看: 437606\|回复: 245	go Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes [复制链接]

轻羽

新手上路

Rank: 1

积分: 0
威望: 0
包包: 0

楼主

发表于 2009-4-22 08:16 |只看该作者 |倒序浏览 |打印

作者：James T. Lane作者单位：Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198-3020


      1 p4 W; M+ u8 z6 y% X$ s
                     , ]9 |* [# ?  E  U- R



         0 a' G0 ~: X6 T
                  7 W+ T( S, z7 m+ u6 J$ O

      % R: S' n" y& J6 ~) N
      6 |8 w- H2 Y; a( z4 y- U! o4 O
      【摘要】
   Microalbuminuria is a marker for diabetic nephropathy. It also signifies cardiovascular disease, as well as nephropathy, in type 2 diabetes (DM2). Microalbuminuria may precede DM2, occurring with the insulin resistance syndrome and its components, including obesity and hypertension. Other indicators of cardiovascular risk, such as markers of inflammation, are associated with microalbuminuria in populations of patients with and without diabetes. With the rising prevalence of DM2 in minority youth, especially in Native Americans, a marker for future disease risk would allow earlier prevention strategies to be tested. Before microalbuminuria can be used in a prevention strategy, more needs to be known about the mechanism(s) of the association between elevated excretion, its relationship to glucose intolerance, and its relative contribution to cardiovascular and renal disease. These questions are especially applicable as we begin to observe the long-term complications of diabetes in youth. ' }1 o4 K6 Z5 e) B$ C- u1 x# [' R
      【关键词】 insulin resistance American Indians young adults
   MICROALBUMINURIA IS A MARKER for diabetic nephropathy and cardiovascular disease in patients with type 1 (DM1) and type 2 (DM2) diabetes mellitus ( 12, 81 - 83, 91, 119 ). Microalbuminuria refers to the excretion of albumin in the urine at a rate that exceeds normal limits but is less than the detection level for traditional dipstick methods ( 4 ). Microalbuminuria has been utilized as a screening test for the presence of diabetes-related kidney disease in patients with DM1. Results are expressed as milligrams per 24-h urine specimen, micrograms per minute in a timed urine specimen, or as micrograms per milligram creatinine in a random spot urine test ( 4 ). Detection of microalbuminuria is important from a clinical standpoint because, once detected, it is an indication for the initiation of anti-angiotensin II therapy with the purpose of preventing or delaying the advance of progressive diabetic nephropathy ( 4, 10, 70, 79, 89, 90 ). Although the positive predictive value of microalbuminuria for progressive diabetic nephropathy is less than once thought, it remains a standard clinical test with important ramifications for patient management ( 12 ).

As noted below, the development of diabetes-related kidney disease is similar in patients with DM1 and DM2 ( 88 ). However, issues involving the time course of the process are blurred by the insidious onset of DM2. In patients with DM2, it has become evident that microalbuminuria is also a predictor of cardiovascular death ( 81 ). However, the presence of microalbuminuria in DM2 may be more reflective of generalized vascular disease than diabetic glomerulopathy.+ B: y5 l/ U: F/ l

The past 10 years have seen a troubling increase in the prevalence of DM2 in youth ( 29, 34, 71, 102, 114 ). This epidemic of DM2 in youth has preferentially affected ethnic minorities ( 29, 71 ). The long-term implications for micro- and macrovascular disease and quality of life are enormous. In an effort to understand the development of DM2 in youth, high-risk populations are being closely monitored with emphasis on early markers of disease. The goal is the development of treatment strategies that will prevent or change the natural history of diabetes and its complications.

The goal of this review is to summarize the evidence supporting an association of microalbuminuria with conditions that may occur before the development of DM2 in high-risk populations, including obesity, the insulin resistance syndrome, and impaired glucose tolerance. First Nation (Canadian North American Indians) and American Indians in North America are highlighted as an example of a high-risk population, but similar data exist for other ethnic groups at high-risk for DM2, including African Americans and Hispanics ( 36 ). It is clear that cardiovascular risk and disease begin before the diagnosis of DM2 in patients with insulin resistance and can be accelerated in young adults. The challenge is to learn more about the temporal pattern of disease markers that reflect disease evolution and why they occur, choose appropriate strategies for intervention, and conduct clinical trials that will prevent both cardiovascular and renal disease in patients at risk.

NATURAL HISTORY OF MICROALBUMINURIA IN DM1 DIABETES
) k, V1 T0 b3 `) a9 x
Microalbuminuria is not usually a presenting finding at the onset of DM1. After a 5- to 10-yr duration of diabetes, susceptible patients develop intermittent microalbuminuria before having persistent microalbuminuria ( 84 ). Improved blood glucose control ( 23a, 110, 117a ), antihypertensive therapy, and anti-angiotensin II therapy ( 10, 27a, 67, 70, 74, 77, 80a, 90, 120 ) have been shown to delay or prevent the progression of microalbuminuria and the development of nephropathy. In DM1, microalbuminuria is a strong risk factor for the development of nephropathy. The development of microalbuminuria is associated with established extracellular matrix expansion in the glomerular and tubulointerstitial compartments of the kidney ( 69 ). The natural history results in progressive glomerulosclerosis, increasing proteinuria, and chronic renal failure. The long period between the onset of microalbuminuria and chronic renal failure (in years) offers a substantial window for therapeutic intervention ( 117 ).

Recent data suggest that microalbuminuria in DM1 may regress over time. Perkins et al. ( 94 ) reported data from the Joslin Clinic on 386 patients with DM1 who were followed for 8 yr ( Table 1 ). Regression was defined as a 50% decrease in albumin excretion from one 2-yr study period to the next 2-yr study period and occurred in 58% of the patients ( 94 ). Interestingly, regression was not associated with angiontensin-converting enzyme inhibitor use but was associated with glycosylated hemoglobin levels of 1 S" l+ x1 G+ ^

Table 1. Human clinical studies of microalbuminuria
; }& L) b0 N5 F. B! {) K5 L3 Z
NATURAL HISTORY OF MICROALBUMINURIA IN DM2
% k8 l. P4 a0 R" z4 f
Because of the insidious onset of DM2, the true duration of the disease is often not known. It has been reported that a 6 yr of diabetes may have existed before diagnosis ( 46 ). Because of the variable duration of disease at diagnosis, subjects often present with microalbuminuria at that point. However, diabetic nephropathy in DM2 is similar to nephropathy in DM1 with similar pathology, response to interventions of glucose control and anti-angiotensin II therapy, and progression to chronic renal failure ( 12, 99 ). DM2 with nephropathy involves a similar proportion of patients, compared with DM1 ( 49 ). At present, there is not a similar long-term study evaluating regression in DM2 as described above for DM1. However, data taken from recent intervention studies using angiotensin II receptor antagonists demonstrate some regression. Lewis et al. ( 70 ) reported on the use of irbesartan in patients with DM2 and nephropathy. A 33% decrease in proteinuria was seen over 2.6 yr, whereas the placebo group decreased 10%. A similar study using losartan in DM2 and nephropathy found a reduction of 35%, whereas the placebo group had a rise in proteinuria ( 10 ). Parving et al. ( 90 ) reported on the use of irbesartan in a population of hypertensive patients with DM2 and microalbuminuria and found that microalbuminuria was decreased by 38% over 2 yr with only a change of 2% in the controls. Attempts at prevention of nephropathy in DM2 have focused on the prevention of microalbuminuria, the earliest clinical hallmark of nephropathy, or its progression to macroalbuminuria ( 89, 99 ). In general, the evolution of nephropathy in DM2 is similar to what is found with DM1.7 y0 J5 g0 o7 c! \8 J/ y/ M

MICROALBUMINURIA IS ASSOCIATED WITH CARDIOVASCULAR DISEASE

Microalbuminuria has been associated with increased cardiovascular mortality in populations of both diabetic and nondiabetic subjects ( 43, 57, 81, 125 ). In fact, microalbuminuria has been used as a marker of cardiovascular disease, along with other risk factors found in the insulin resistance syndrome. Data from the Framingham Offspring Study suggest that microalbuminuria is more likely to be present with additional cardiovascular risk factors ( 78 ). The premise is that microalbuminuria is a marker of generalized endothelial dysfunction. Microalbuminuria has been linked to increased transcapillary albumin leakage and increased von Willebrand factor and other markers of endothelial dysfunction ( 59, 106 ). In survivors of myocardial infarction, both albuminuria and the transvascular escape rate of albumin are increased ( 58 ). Albuminuria has also been shown to predict the severity of atherosclerosis ( 86, 116 ). Others have suggested that the elevated insulin levels that occur with insulin resistance increase glomerular hemodynamic pressures that increase albumin excretion ( 16, 115 ). The relative contribution of underlying vascular disease vs. diabetic nephropathy toward microalbuminuria is not clear. However, a large body of evidence suggests that microalbuminuria is an indicator of both micro- and macrovascular disease.

Cross-sectional studies have clearly demonstrated the presence of microalbuminuria with other markers of the insulin resistance syndrome. Using clamp studies, hypertension alone was found to associate with a decrease in glucose disposal by 27% ( 37 ). However, the combination of microalbuminuria and hypertension was associated with the greatest decrease in glucose disposal. The highest triglycerides and the lowest HDL-C levels, additional markers of the insulin resistance syndrome, were associated with patients having hypertension and microalbuminuria. In the Botnia Study, 84% of those with DM2 had elements of the insulin resistance syndrome (obesity, hypertension, dyslipidemia, or microalbuminuria) ( 55 ). If present, the insulin resistance syndrome increased the risk for coronary artery disease and stroke threefold. However, microalbuminuria was the strongest risk for cardiovascular death. Of those with normal glucose tolerance, 10% had microalbuminuria, suggesting the potential for microalbuminuria as a marker for the risk of coronary artery disease in nondiabetic individuals. This is such an important association that the World Health Organization has included microalbuminuria in its definition of the metabolic syndrome ( 2 ).2 E5 i; m; V# \' W# k" N

MICROALBUMINURIA AS A RISK FACTOR IN NONDIABETIC PEOPLE" I7 T% w, O- ~; J. \
% `# V0 w$ e4 R* A) y; Q! M2 O
A number of studies have demonstrated that microalbuminuria occurs in individuals without diabetes. In the Mexico City Diabetes Study, nondiabetic people with microalbuminuria were more likely to have a family history of diabetes ( 42 ). Similar findings were reported by in the Botnia study, where first-degree relatives of patients with DM2 demonstrated insulin resistance in association with elevated albumin excretion rates ( 32 ). In the Insulin Resistance Atherosclerosis Study, patients with microalbuminuria were more insulin resistant and had higher fasting insulin concentrations compared with patients without microalbuminuria ( 87 ). However, the relationship was also partially dependent on blood pressure and obesity. Although the bulk of the data supports microalbuminuria as being a component of the insulin resistance syndrome, not all results support this contention ( 56 ). The Hoorn Study evaluated a homogenous Caucasian population and found that microalbuminuria was associated with hypertension, DM2, and waist-hip ratio. It did not, however, associate with other components of the insulin resistance syndrome. This raises the alternative view that microalbuminuria is associated with hypertension but not the insulin resistance syndrome. In Data from an Epidemiological Study on the Insulin Resistance Syndrome findings, the cardiovascular events were greater in subjects with microalbuminuria ( 45 ). However, in contrast to men, women did not show the same increased cardiovascular risk with the addition of microalbuminuria. A similar trend was seen in the Inter-Tribal Heart Project, where nondiabetic Native Americans with microalbuminuria often had the insulin resistance syndrome ( 52 ). Thus hormonal differences may play a role in the expression of the increased cardiovascular risk in patients with insulin resistance and microalbuminuria. Although this may suggest that estrogen may have some protective effect, when women are administered estrogen in the preor postmenopausal setting, it is associated with increases in microalbuminuria in a dose- and time-dependent fashion ( 85 ). In addition, in women high levels of microalbuminuria, when present, are still predictive of cardiovascular disease, as demonstrated in an epidemiological study from The Netherlands in which women with the highest quintile of microalbuminuria were at increased risk of cardiovascular death ( 101 ).7 W" y8 K6 i" f. |# A
  I" m( R  Y, [9 p8 i. z
Such terms as the "ticking clock" or the "common soil" hypothesis have been used to suggest that the time course for the development of cardiovascular disease begins before the onset of clinical diabetes ( 44, 107 ). The common factors for the development of cardiovascular disease may represent genetic or environmental factors that are present before the clinical manifestations of disease. Indeed, in the Nurses' Health Study, the risk for cardiovascular disease was found to be elevated at least 15 yr before the diagnosis of diabetes ( 53 ). Whether the common factors for onset of microalbuminuria and diabetes are preventable is of great interest for future therapy. The Heart Outcomes and Prevention Evaluation study provided powerful data along these lines ( 73 ). The use of the ACE inhibitor ramipril reduced the progression of albuminuria, whether this was new albuminuria or the progression of microalbuminuria to macroalbuminuria. This study also demonstrated that ramipril was effective in decreasing cardiovascular death in patients with known heart disease or DM2 patients without established heart disease. The benefits of ramipril were greatest on preventing cardiovascular events in patients with DM2 and in nondiabetic patients with albuminuria.! ]. X# ^; M0 W5 P7 w! Z: F
) i( e% Z2 Q. M! Q! n3 R" N" h
DM2 IS INCREASING IN YOUTH
6 s& S4 j4 w( X% s! O5 _
Over the past 20 years, the prevalence of DM2 has increased 18% in the United States ( 3 ). Not only is DM2 more prevalent, but it often begins at a younger age ( 71, 102 ). This has serious consequences for long-term health as these patients are also at increased risk for cardiovascular disease, end-stage renal disease, blindness, amputation, and the associated personal and economic losses at earlier ages. The younger onset of patients with DM2 suggests that those patients will live with complications for a larger percentage of their lifetime.1 E- F5 D3 V0 ?7 D) A

Prevalence rates for diagnosed DM2 in children have been estimated at between 2 and 50/1,000, depending on the population studied, whereas that for the general adult population is 30/1,000 ( 29 ). Those children and young adults with the highest prevalence rates of DM2 are from racial and ethnic minorities, including African Americans, Hispanics, and Native Americans ( 29, 71 ). The increased prevalence of DM2 in children has been attributed to increasing obesity, a sedentary lifestyle, and increased intrauterine exposure to a diabetic environment ( 8, 29, 34, 71, 114 ). The degree of obesity is significant, as most published studies have found that affected children with DM2 have a mean body mass index (BMI) exceeding the 95th percentile for age ( 29, 71 ). Because of the increased prevalence of DM2, DM1 may no longer represent the most common form of diabetes in youth, as up to 50% of new cases of diabetes in youth are DM2 in some populations ( 71 ).3 n8 u/ |" k$ C

DM2 IS INCREASED IN NATIVE AMERICANS, INCLUDING YOUTH" l  p$ K' i. L
$ `  o2 ~6 B! R" S6 H
DM2 is epidemic in American Indian populations ( 3, 11 ). Data from the Indian Health Service suggest that the prevalence rate is 8.0%, over double the rate for the population as a whole ( 14 ). There is also a female predominance, with prevalence rates 25% higher in American Indian females ( 13 ). The prevalence rates for other minorities, including African Americans and Hispanics, are similar to those of American Indians ( 3 ).9 j) S3 c( @) w( r% O

Similar to national trends, American Indian children and youth are also experiencing an increased prevalence of DM2 ( 20, 21, 29, 47 ). Numbers for American Indians across the U.S. vary from 1.3/1,000 for children 0-14 yr of age to 4.5/1,000 for youth aged 15-19 yr ( 29 ). Recent Indian Health System data indicate the prevalence rate has risen to 5.4/1,000 for ages 15-19 yr, an increase of 68% over a decade ( 1, 7 ). Population-based studies demonstrate that DM2 occurs in African Americans at a rate of 7.2/1,000, in contrast to 4.1/1,000 for all U.S. adolescents aged 12-19 yr ( 29 ). Without a plateau in the increasing prevalence, DM2 will be expected to increase into the future." @& w' B4 I! i+ i

MICROALBUMINURIA IN AMERICAN INDIAN CHILDREN AND ADULTS

The prevalence of microalbuminuria amongst all American Indian tribes is not known. However, the Strong Heart Study recently revealed the prevalence of microalbuminuria in Arizona, Oklahoma, and Dakota Indians to be 28.3, 15.2, and 13.8%, respectively ( 100 ). However, these subjects were all adults and may not represent the prevalence of microalbuminuria in young American Indians.* k/ d) t+ X0 e6 P) P
9 ?1 l) P4 `/ X3 R7 B( t
Fagot-Campagna et al. ( 28 ) reported on the prevalence of cardiovascular risk factors, including microalbuminuria, in Pima children age 5-19 yr. The group included 4,092 10- to 19-yr-old patients with normal glucose tolerance. At baseline, 6% had microalbuminuria, whereas 8% with impaired glucose tolerance had microalbuminuria. After more than 5 yr, 33% of the entire cohort had developed microalbuminuria. This is in contrast to the rates of microalbuminuria in other healthy ethnic groups. For African Americans, 7.7% of men and 10.5% of women aged 6-19 yr have microalbuminuria ( 60 ). Non-Hispanic whites (5.7/9.7, men/women) and Hispanics (5.4/9.5, men/women) have lower rates of microalbuminuria. After age 19, in all ethnic groups the rate of microalbuminuria falls in the third decade to rates roughly one-half those seen at ages 6-19 yr. If microalbuminuria serves as a marker of future cardiovascular and renal disease, efforts to define its prevalence in high-risk populations are an essential first step to a prevention strategy.& h! ?+ W6 B) Y- y! ~2 K' i

ROLE OF PUBERTY IN DEVELOPMENT OF MICROALBUMINURIA% s9 \7 _1 l; o$ H' {
+ s" |$ L. ]7 Y9 ~! b
Puberty is normally associated with complex changes in renal hemodynamics, somatic growth, and changes in sex hormones that may have important interactions with hyperglycemia and insulin resistance ( 68 ). These changes may, in turn, affect microalbuminuria during puberty. It is rare to develop microalbuminuria before puberty in DM1. In fact, there has been a suggestion that diabetic nephropathy does not occur before puberty ( 24, 65 ). Although patients may not have microalbuminuria, histological changes indicative of diabetic nephropathy occur in association with duration of diabetes, not pubertal stage ( 25 ). However, with DM2, pathological insulin resistance may interact with developmental changes to accelerate the onset of microalbuminuria.
) y( d# J$ d2 `% A: A; q) h
Puberty is associated with changes in insulin sensitivity ( 5, 9, 17, 95 ). Tanner staging characterizes pubertal development, according to physical findings utilizing examination of pubic hair and genitalia in boys and pubic hair, breast size, and menarche in girls ( 75, 76 ). Tanner stages range from stages 1 (preadolescent) to 5 (fully mature). Several studies have demonstrated that insulin sensitivity decreases early in puberty in nondiabetic children as well as patients with diabetes, beginning between Tanner stages 1 and 2 and decreasing throughout puberty. Insulin sensitivity improves to normal after linear growth is complete in adults. Body fat also increases in early puberty, but BMI does not change with Tanner stage in adolescents.

No clear association between insulin sensitivity and rising sex steroid concentrations has been found in men ( 123 ). However, polycystic ovary syndrome with its proatherosclerotic effects ( 123 ) often includes increased androgens. It has been recently reported that higher free androgen levels in children with DM1 were associated with the development of microalbuminuria ( 6 ).

Several studies have implicated a relationship between insulin sensitivity and the growth hormone-IGF-1 axis, suggesting increased tissue growth hormone effect as the cause ( 9, 17 ). One study found a significant association among IGF-1, renal hypertrophy, and microalbuminuria ( 19 ). However, others did not confirm this relationship ( 104 ). To date, studies evaluating microalbuminuria during puberty have been cross sectional. Additional prospective studies are needed to more closely characterize the changes that occur with puberty and the development of microalbuminuria." p# i. W3 Z6 g+ s( U$ k8 k+ C
/ B; ~* y6 P! Z6 @- a7 N6 x' R$ D
ASSOCIATION OF CARDIOVASCULAR DISEASE WITH MARKERS OF INFLAMMATION
2 y, T0 f8 L0 ~: X5 J
The use of the highly-sensitive C-reactive protein (CRP) assay, a sensitive marker of inflammation, has been shown in a number of studies to predict the risk of cardiovascular disease events ( 15, 51, 64, 66, 93, 96 - 98, 112, 113, 128 ). An active role for elevated CRP levels in the pathophysiology of vascular disease has been suggested but not definitively proven ( 23, 92, 122, 129 ). Because microalbuminuria, CRP, and other markers of inflammation have been shown to be associated with cardiovascular disease, the question arises as to whether the inflammatory process causes the microalbuminuria.

A large cross-sectional study has demonstrated an association between microalbuminuria and CRP ( 31 ). Festa et al. ( 31 ) reported on 1,281 subjects from the Insulin Resistance Atherosclerosis Study. The study population contained patients with and without DM2. There was a positive association between microalbuminuria and elevated CRP and fibrinogen. The association was similar across gender and ethnic groups. The authors suggest that the association may arise from three possibilities: the independent development of atherosclerosis and microalbuminuria, the direct or indirect effect of cytokines on the glomerulus, or the presence of both from a common preexisting condition. However, a retrospective analysis of the Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study did not demonstrate an association between microalbuminuria and CRP levels in a population at high risk for DM2 ( 111 ).1 G0 }1 B( H% }
% O& c+ S1 g( K1 P! J6 i2 N  Y
Stehouwer et al. ( 105 ) prospectively followed markers of chronic inflammation and endothelial dysfunction in 328 patients with DM2 for 9.0 yr. Markers for both endothelial dysfunction and chronic inflammation, as well as microalbuminuria, were found to be interrelated, to have developed in parallel, progressed with time, and were related to death." H0 N# a# t; m) i6 I7 [( k
' m1 e+ Z5 v# p5 c
Stuveling et al. ( 108 ) reported on 7,317 patients without diabetes. CRP was associated with microalbuminuria and decreased renal filtration as measured by creatinine clearance. CRP was also associated with hyperfiltration (defined by an elevated creatinine clearance and seen before a decrease in creatinine clearance in patients with diabetic nephropathy), although this relationship was primarily related to BMI and has been described previously ( 80, 118 ). These data raise the point that inflammatory processes may negatively impact renal function, as well as cardiovascular end points. This may be especially true in individuals who progress from obesity to prediabetes to diabetes. No prospective data exist in patients with diabetes to provide insight into this question.
7 I+ f# h4 h1 l/ a
Obesity, especially visceral obesity, has been previously associated with plasma inflammatory markers, including IL-6, CRP, and TNF- ( 18, 50, 62, 121, 126, 127 ). BMI and hemoglobin A1C have also been associated with inflammatory markers ( 105 ). Acute hyperglycemia has been shown to increase IL-6, TNF-, and IL-18 ( 27 ). Low levels of adiponectin that occur with obesity are associated with increased IL-6 and CRP plasma levels ( 26 ). Visceral obesity is also associated with increased free fatty acid release into the portal vein ( 33 ). This leads to increased hepatic glucose output with resultant hyperglycemia and decreased hepatic insulin extraction with resultant hyperinsulinemia ( 30, 109 ). Glowinska et al. ( 35 ) reported that traditional risk factors for cardiovascular disease, such as hypertension and dyslipidemia, are also associated with nontraditional risk factors, such as decreased fibrinolytic activity and homocysteinemia, and lipoprotein (a) levels in obese, diabetic adolescents.8 ~1 r  C9 a! t
  T% R. x3 }5 ~# M2 i+ H
These findings suggest that prevention of obesity, prevention of hyperglycemia, use of antioxidants, and other anti-inflammatory treatments may be beneficial in addressing the early progressive inflammatory response associated with diabetes and vascular disease. Indeed, glutathione has been shown to prevent the rise of cytokine levels ( 27 ). The increase in oxidative stress from obesity was further supported in a community-based cohort in the Framingham Heart Study ( 61 ). Thiazolidinediones increase adiponectin levels ( 72, 124 ). Salicylates may improve fat-induced insulin resistance ( 63 ). Exercise is associated with decreased CRP levels ( 54 ). These are in addition to lifestyle changes to lose weight.! f" p; m  {; X
6 X" f% {% }$ R2 j$ ?2 e
CLINICAL USE OF THE MICROALBUMIN ASSAY

Although there are clear recommendations for the measurement of microalbumin excretion in the urine, the test is not universally employed ( 48 ). Factors contributing to this include lack of availability, confusion with units of measure, increased turnaround time for the assay, and the sense by clinicians that such measurements are not needed provided patients are placed on an angiotensin-converting enzyme inhibitor or angiotensin II blocker. The latter point is incorrect for several reasons. Despite therapy with one of the renoprotective agents, there is now evidence that simultaneous use of both agents may further decrease microalbuminuria, and prospective testing needs to be performed to titrate the medications ( 103 ). The above review has also indicated that microalbuminuria is a marker of vascular disease and can be used to support further therapy directed at this complication. For the stated reasons, the recommendations for microalbuminuria testing need to be emphasized and the obstructions to its use removed., R; ~' E* l6 T
3 W* a7 w  y" h
SUMMARY3 J1 x4 s2 b$ y% q, I, e: s2 s

There is generally a long lag time between the initiation of atherogenesis and the first cardiac event, which provides an opportunity to intervene with preventive therapy in insulin resistance. However, before a prevention treatment can be devised and tested, more needs to be known about the temporal development of DM2, vascular disease, and renal disease. Evidence already exists of the terrible toll of diabetes and its complications occurring earlier in youth who develop diabetes. Dean and Flett ( 22 ) reported a high mortality rate of 9% after 15 yr of diabetes in First Nation populations in Manitoba and Ontario, Canada. These patients were diagnosed with DM2 before 18 yr of age and were only in their third decade of life when they died. As insulin resistance and diabetes become more prevalent, its complications loom threateningly on the horizon for these patients.2 X5 w2 ?- O) t; o4 r1 c
% h( R4 |0 V" G( Z
The pathophysiology of insulin resistance and diabetes-related vascular disease likely begins before the diagnosis of DM2 ( Fig. 1 ). Inflammatory markers begin to increase with the presence of visceral obesity. Microalbuminuria is another marker of endothelial dysfunction, which may occur with early cardiovascular and renal disease. While microalbuminuria is also a marker of early diabetic nephropathy and may not always predict progression, it appears to also predict significant cardiovascular disease. Further understanding of these issues is critical to prevent mortality from cardiovascular and renal disease in diabetes, especially in young adults with DM2.4 I, {6 Y- D' \1 N6 {
8 w! v$ L/ i4 ^) n. s6 F/ C
Fig. 1. Model for the development of cardiovascular and renal disease in patients with a variety of disorders surrounding insulin resistance and glucose intolerance. It should be noted that microalbuminuria has been found as a marker of these conditions, evident before diabetes, and may serve as a marker of disease activity.
3 t+ K* ]5 R# k  g- m* n
Address for reprint requests and other correspondence: J. T. Lane, Dept. of Medicine, Nebraska Medical Center, Omaha, NE 68198-3020 (E-mail: jtlane1{at}unmc.edu 2 w" }4 C$ @6 c, r9 |( C
      【参考文献】
Acton K, Burrows N, Moore K, Querec L, Geiss L, and Engelgau M. Trends in diabetes prevalence among American Indian and Alaska native children, adolescents, and young adults. Am J Public Health 92: 1485-1490, 2002.

: D, R0 ~# z8 j# Y! F
! ]8 o( H  z8 y1 G$ J
Alberti K and Zimmet P for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998. <a href="/cgi/external_ref?access_num=10.1002/(SICI)1096-9136(199807)15:7

/ s) b; R7 W) G+ r

American Diabetes Association. Diabetes statistics. In: Diabetes 2001; Vital Statistics, edited by Raynor J. Alexandria, VA: American Diabetes Assoc., 2001, p. 13-27.

9 |  A! v0 }( b3 {' r; E2 K' U6 u
American Diabetes Association. Diabetic nephropathy. Diabetes Care 26, Suppl 1: S94-S98, 2003., |8 ^* ]& j1 h. E
6 j+ o8 c# m) }% _2 U" S

Amiel S, Sherwin R, Simonson D, Lauritano A, and Tamborlane W. Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315: 215-219, 1986.

! f% r  o$ N/ s+ U# \5 x0 M

Amin R, Schultz C, Ong K, Frystyk J, Dalton R, Perry L, Orskov H, and Dunger D. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects. Diabetes Care 26: 1456-1461, 2003.$ f$ B5 ]% S& i* E! z; D0 g# Z0 c

Arslanian S. Type 2 diabetes in children; clinical aspects and risk factors. Horm Res 57, Suppl 1: 19-28, 2002.
( j$ a, d) n3 \& L- K. u! A( Q, {

Blair S and Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 31, Suppl 11: S646-S662, 1999.2 G4 j5 r8 ]" a4 g

8 M' B# l: O$ T; c" v% K. n( d! x
Bloch C, Clemons P, and Sperling M. Puberty decreases insulin sensitivity. J Pediatr 110: 481-487, 1987.. s  P1 o4 \( e8 u8 \: E
8 c% {( H% h# I8 j
# h/ w4 K6 r6 R( ]9 M$ f' N# \: ]* z
0 Z/ y. q# [+ _- b, D; v, @# F5 K
Brenner E, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, Snapinn S, Zhang Z, and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.

Burrows N, Geiss L, Engelgau M, and Acton K. Prevelance of diabetes among Native Americans and Alaska natives. Diabetes Care 23: 1786-1790, 2000.

Caramori M, Fioretto P, and Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49: 1399-1408, 2000.+ |; S, _) ]  _0 o' k9 }, S
9 f/ l1 T, w! T8 b1 e
+ U  S+ J" J+ P5 z2 u$ J

Centers for Disease Control and Prevention. Diabetes Surveillance, 1999. Atlanta, GA: Dept. of Health and Human Services, Public Health Service, 1999.& x& C* t% W+ c
: q; m  b- U3 E
5 i% j3 C5 t  D

Centers for Disease Control and Prevention. Prevalence of selected risk factors for chronic disease and injury among American Indians and Alaska Natives-United States, 1995-1998. MMWR 49: 79-82, 91, 2000.

Cermak J, Key N, Bach R, Balla J, Jacob H, and Vercellotti G. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82: 513-520, 1993.- X/ Z" f. a8 I' q" J  {
8 f8 {' q  w2 p7 y+ Z8 j& K& t

% k+ H5 f, Y. `- N7 T
Cohen A, McCarthy D, and Stoff J. Direct hemodynamic effect of insulin in the isolated perfused kidney. Am J Physiol Renal Fluid Electrolyte Physiol 257: F580-F585, 1989.9 D8 I3 Y  |% ~4 M9 Q" ^

: r& z2 H, d+ J: d! ^0 X' b

Cook J, Hoffman R, Stene M, and Hansen J. Effects of maturational stage on insulin sensitivity during puberty. J Clin Endocrinol Metab 77: 725-730, 1993.

Corica F, Allegra A, Corsonella A, Buemi M, Calapai G, Ruello A, Mauro VN, and Ceruso D. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. Int J Obes 23: 355-360, 1999.

6 x) k5 |! {9 w5 Q+ v* W

Cummings E, Sochett E, Dekker M, Lawson M, and Daneman D. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 47: 1341-1346, 1998.. K6 ]3 h9 J0 w) H& k: ~

1 x5 v2 D, J' Y' T

Dabelea D, Hanson R, Bennett P, Roumain J, Knowler W, and Pettitt D. Increasing prevalence of type II diabetes in American Indian children. Diabetologia 41: 904-910, 1998.4 }8 M5 B0 {" ]8 r' X: g6 |

, K0 G' ^- s/ o. V6 ?$ u
Dabelea D, Pettitt D, Hanson R, Imperatore G, Bennett P, and Knowler W. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care 22: 944-950, 1999.
3 Q% [9 w; `* h# i4 \0 ]3 z, }  ^

Dean H and Flett B. Natural history of type 2 diabetes diagnosed in childhood: long term follow-up in young adult years. Diabetes 51, Suppl 2: A25-A26, 2002.

* e: g- g  D9 r1 C6 N4 E& o* L
Devaraj S, Xu D, and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implications for the metabolic syndrome and atherothrombosis. Circulation 107: 398-404, 2003.

5 \- |+ k0 h# S: s5 I( I
Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
9 g9 E0 _! ~' Y0 k0 s* k# m
. ~' l6 n9 a, d9 P
1 [# T  f" h# v2 V- l9 k, d
Donaghue K, Fairchild J, Craig M, Chan A, Hing S, Cutler L, Howard N, and Silink M. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 26: 1224-1229, 2003.' e7 J5 O5 H6 J4 c

! ~" L) b* i/ {9 w( X4 i
5 m* j* o4 V8 J" R- U* {. s; f
Drummond K, Kramer M, Suiissa S, Levy-Marchal C, Dell'Aniello S, Sinaiko A, and Mauer M. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 52: 1818-1824, 2003." Q" F& _1 _2 q0 ?, P3 f
# U2 y+ Z( y$ z& u
" T; E" M! ^6 k2 C, A/ U
1 g$ \2 s$ z/ d, v5 S1 r; K) W9 H
Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Mohlig M, Pfeiffer A, Luft F, and Sharma A. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942-947, 2003.
3 q* l$ F: Q) w) a) ^" u8 T

Esposito K, Nappo F, Marfella R, Giujgliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, and Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072, 2002.
  f, N% X& D0 a

The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792, 1997.
4 m) C( q. v0 \6 f+ u

Fagot-Campagna A, Knowler W, and Pettitt D. Type 2 diabetes in Pima Indian children: cardiovascular risk factors at diagnosis and 10 years later (Abstract). Diabetes 47, Suppl 1: A155, 1998.

Fagot-Campagna A, Pettitt D, Engelgau M, Burrows N, Geiss L, Valdez R, Beckles G, Saaddine J, Gregg E, Williamson D, and Narayan KV. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136: 664-672, 2000.
7 u# [- K: x, Z9 O( o" S/ B3 T. @
. H- k: u1 s9 U- p9 T: V3 _
/ W  ^( i/ D0 F$ q- b/ h6 h2 J: I" x
Ferrannini E, Barrett E, Bevilacqua S, and DeFronzo R. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737-1747, 1983.- U* e" Z9 k$ X
$ R6 F. k+ E- y% M, G" k
6 f! r* n: v% R& T- T7 F3 p/ r2 C

Festa A, D'Agonstino R, Howard G, Mykkanen L, Tracy R, and Haffner S. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 58: 1703-1710, 2000.- y5 d$ \% ?  S5 N3 A' c
9 {5 r+ `- [+ V; @

Forsblom C, Eriksson J, Ekstrand A, Teppo A, Taskinen M, and Groop L. Insulin resistance and abnormal albumin excretion in nondiabetic first degree relatives of patients with IDDM. Diabetologia 38: 363-369, 1995.

Frayn K. Visceral fat and insulin resistance: causative or correlative? Br J Nutr 83: S71-S77, 2000.
) A, D3 e6 Z6 Q' p( S
5 B2 k* [& j1 t

Glaser N. Non-insulin dependent diabetes mellitus in childhood and adolescence. Pediatr Clin North Am 44: 307-337, 1997.
8 F8 B( t5 A3 ]

Glowinska B, Urban M, Koput Q, and Galar M. New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis 167: 275-286, 2003.
/ G) N7 S& `' n# s

Goran M, Ball G, and Cruz M. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 88: 1417-1427, 2003.

1 f/ K3 E- u, r' v

Groop L, Ekstrand A, Forsblom C, Widen E, Groop P, Teppo A, and Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 642-647, 1993.

4 n2 |9 v8 H- c) C$ s; X: E9 d
Haffner S, Gonzales C, Valdez R, Mykkanen L, Hazuda H, Mitchell B, Monterrosa A, and Stern M. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia 36: 1002-1006, 1993.
) W" |' R; c/ U1 [% H% r- Q

Haffner S, Stern M, Gruber M, Hazuda H, Mitchell B, and Patterson J. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10: 727-731, 1990.
4 \; x1 }5 L2 N& _
  g3 c- F  U  Z: N! q
% y+ B6 I& }; y5 S( C3 c, x
Haffner S, Stern M, Hazuda H, Mitchell B, and Patterson J. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263: 2893-2898, 1990.
8 g* c4 @. h4 n- F2 l; W) A& S6 n
7 C2 h: R/ @0 T

Halimi J, Forhan A, Balkau B, Novak M, Wilpart E, Tichet J, and Marre M. Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovas Risk 8: 139-146, 2001.8 w6 H% \7 e, o& U8 y5 i" n8 R; G  [

; }! S% `1 n- l# F' b8 B" V

Harris M, Klein R, Welborn T, and Knuiman M. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 15: 815-819, 1992.

7 y6 [, T3 c& ?- ~

Harwell T, McDowall J, Moore K, Fagot-Campagna A, Helgerson S, and Gohdes D. Establishing surveillance for diabetes in American Indian youth. Diabetes Care 24: 1029-1032, 2001.
) B; y3 K/ C+ p4 o. L

Harwell T, Nelson R, Little R, McDowall J, Helgerson S, and Gohdes D. Testing for microalbuminuria in 2002: barriers to implementing current guidelines. Am J Kidney Dis 42: 245-248, 2003.

Hasslacher C, Ritz E, Wahl P, and Michael C. Similar risks of nephropathy in patients with type 1 or type 2 diabetes mellitus. Nephrol Dial Transplant 4: 859-863, 1989.
( r, E1 x" z; p+ }" K1 x/ f  e
$ x) S- C" m* a3 U4 ^

Hauner H, Bender M, Haastert B, and Hube F. Plasma concentrations of soluble TNF- receptors in obese subjects. Int J Obes 22: 1239-1243, 1998.

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M, and The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349: 462-466, 1997.
# }4 [/ h* s  a' C3 V/ @$ Y# n  C

Hoehner C, Greenlund K, Rith-Najarian S, Casper M, and McClellan W. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13: 1626-1634, 2002.

0 D- r5 e: s: T4 X/ Y8 M
Hu F, Stampfer M, Haffner S, Solomon C, Willett W, and Manson J. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25: 1129-1134, 2002.

. T1 A" }2 F& E7 n( _

Isasi C, Deckelbaum R, Tracy R, Starc T, Berglund L, and Shea S. Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. Pediatrics 111: 332-338, 2003.  m$ _- W  c5 |/ ?# W1 t- M% l

  ]1 ]! y& Y* v: @/ s$ m) [7 X& p
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M, and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
3 c2 M* x# X, p: o5 W# R
5 G( i: V$ z, T2 y3 H$ `
! Y* t2 K9 l! o3 e1 ~! E; s
Jager A, Kostense P, Nijpels G, Heine R, Bouter L, and Stehouwer C. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 41: 694-700, 1998.

) h1 L, u7 p0 v& ^  h5 r

Jarrett J, Viberti G, Argyropoulos A, Hill R, Mahmud U, and Murrells T. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabet Med 1: 17-19, 1984.& P" U6 s/ b% A9 Y7 M) A% N

! s! }" ~  M- d, T
, T& ]- w1 T1 |" }' y7 h% x
Jensen J. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arteriolscler Thromb Vasc Biol 15: 1324-1329, 1995.
( C. C# Q% P- j/ E+ V, |+ ^3 R* _
( y$ @+ F  F0 [
4 u4 N. ?' N. {6 G4 m9 r) p* i
Jensen T, Bjerre-Kundsen J, Feldt-Rasmussen B, and Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1: 461-463, 1989.

Jones C, Francis M, Eberhardt M, Chavers B, Coresh J, Engelgau M, Kusek J, Byrd-Holt D, Narayan K, Herman W, Jones C, Salive M, and Agodoa L. Microalbuminuria in the US Population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 39: 445-459, 2002.
: O& [  P0 I- R9 `1 W- [4 i/ d

- j5 S; Y" l) q- p
Keaney J, Larson M, Vasan R, Wilson P, Lipinska I, Corey D, Massaro J, Sutherlaned P, Vita J, and Benjamin E. Obesity and systemic oxidative stress. Clinical correlates of oxidative stress in The Framingham Study. Arteriolscler Thromb Vasc Biol 23: 434-439, 2003.- }# }4 K1 c: G+ c; O+ X# }
& K8 Y0 l+ g4 I2 F! B! F& C
0 F2 _) D. f/ I4 ~) R
. d, k) V0 m( m* O# o8 t
Kern P, Ranganathan S, Li C, Wood L, and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751, 2001.

5 r) A( g2 c1 w' p% E
- ^# G3 L1 E; X+ h9 A* J: ?. G
Kim J, Kim Y, Filmore J, Chen Y, Moore I, Lee J, Yuan M, Li Z, Karin M, Perret P, Shoelson S, and Shulman G. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108: 437-446, 2001." U* U9 B$ M: b, S9 E; G
( J" V4 ]6 d4 M4 J+ ?

: |( n; x. n2 D) e
Koenig W, Sund M, Rohlich M, Fischer HG, Lowel H, Doring A, Hutchinson W, and Pepys M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 99: 237-242, 1999.

Krolewski A, Warram J, Christlieb A, Busick E, and Kahn C. The changing natural history of nephropathy in type I diabetes. Am J Med 78: 785-794, 1985.7 V" r1 F7 Y3 U  t( U' i
7 K; z( w0 S+ s5 W+ |6 I

) [* n# |  `3 o' A9 m  ]
Kuller L, Tracy R, Shaten J, Meilahn E, and the Multiple Risk Factor Intervention Trial Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144: 537-547, 1996.

1 s" b* K& l& s- t- B

Laffel L, McGill J, and Gans J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99: 497-504, 1995.) I) p2 V, Y5 n+ G! v& R2 b% X6 q
0 x( g! I! r$ n0 V6 B
) E& T0 u/ y% \1 `* P; o: T/ y
( C" Y! J; t2 q. i$ H7 p! v
Lane P. Diabetic kidney disease: impact of puberty. Am J Physiol Renal Physiol 283: F589-F600, 2002.
1 {: i; E0 L4 p- ?) \. t  {

Lane P, Steffes M, Fioretto P, and Mauer S. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43: 661-667, 1993.6 n7 c& Q) j; L

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rohde B, and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.+ |5 }2 l3 }$ N
  q) _% `  P; Y% x0 W4 h" O& i3 n9 j7 \  u5 H
' a0 g7 R" _9 Z& _4 }

Ludwig D and Ebbeling C. Type 2 diabetes mellitus in children: primary care and public health considerations. JAMA 286: 1427-1430, 2001./ o& L: s! |% K3 R+ u7 V; ?- v5 C

3 U4 e9 X7 I( D( c
Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Jyrutana G, Gitta J, Nakmura T, Shimomura I, and Matsuzawa Y. PPAR ligands increase expression and plasma concentrations of adiponectin, and adipose-derived protein. Diabetes 50: 2094-2099, 2001.
. E4 N7 r3 o* I5 o2 y: h( d

Mann J, Gerstein H, Yi Q, Lonn E, Hoogwerf B, Rashkow A, and Yusuf S. Development of renal disease in people at high cardiovascular risk: results of the HOPE Randomized Study. J Am Soc Nephrol 14: 641-647, 2003.
7 b4 J' i8 y3 z: B7 l) z1 n
8 }+ p4 l$ u* a) i

Marre M, Leblanc H, Suarez L, Guyenne T, Menard J, and Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ 294: 1448-1452, 1987.
# ?$ m( V( Q5 p" }; j
1 e' Z! I4 z$ @
; i$ `7 h6 h9 ^( ]2 c- c; F
Marshall W and Tanner J. Variation in the pattern of pubertal changes in boys (Abstract). Arch Dis Child 45: 13, 1970.
: o. H* J5 K1 i/ b% z9 o
& I  j) R4 p" \0 o% k* `9 t

Marshall W and Tanner J. Variation in the pattern of pubertal changes in girls. Arch Dis Child 44: 291, 1969.% f8 {& G& C, z
. R3 _4 }" \) n8 G
" v: ^0 D' B- I# s$ B% J2 ^
6 d# ^# e  p1 \& r
Mathiesen E, Hommel E, Giese J, and Parving H. Efficacy of captropril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. BMJ 303: 81-87, 1991." H1 T$ v, }; T/ O, D. P

Meigs J, Jacques P, Selhub J, Singer D, Nathan D, Rifai N, D'Agostino R, and Wilson P. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framiningham Offspring Study. Diabetes Care 24: 1403-1410, 2001.! w: h5 F2 U: {9 \: h3 ^/ a9 n3 a5 y
8 [7 U; l' H6 r: L) G9 l  K
( {  h8 C6 x6 E3 c$ C* Y0 N

Meltzer S, Leiter L, Daneman D, Gerstein H, Lau D, Ludwig S, Yale J, Zinman B, and Lillie D. Clinical practice guidelines for the management of diabetes in Canada: Canadian Diabetes Association. Can Med Assoc J 159, Suppl 8: S1-S29, 1998.

( [4 M" ?  U+ Z0 N
. b+ [0 m4 p5 E
Mendall M, Patel P, Ballam L, Strachan D, and Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312: 1061-1065, 1996.9 |4 ?. {5 q- `% _6 A& K* n

6 [0 }9 I9 S1 f6 Q( P6 f
" r1 _" X8 e8 h( e) H% S
Microalbuminuria Collaborative Study Group. Intensive therapy and progressive to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 311: 973-977, 1995.

0 q! n4 F0 o" u  k; ^
Mogensen C. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360, 1984.

+ \2 i% M. m! V' r, |
Mogensen C, Chachati A, Christensen C, Close C, Deckert T, Hommel E, Kastrup J, Lefebvre P, Mathiesen E, Feldt-Rasmussen B, Schmitz A, and Viberti G. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 9: 85-95, 1985.9 g' }4 L& j! C: r& w7 F

& ]  y  e% P& j2 J( z
Mogensen C and Christensen C. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89-93, 1984.

Mogensen C, Christensen C, and Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32: 64-78, 1983.
! ^' o8 C2 R$ [4 u, Q: Q( H
' w0 e  ~+ f0 ~: r
% R2 M* ^0 N7 @4 G( U  T9 r8 A
Monster T, Janssen W, Jong PD, and de Jong-van den Berg LTW. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161: 2000-2005, 2001.
( M" l. e/ w6 a

Mykkanen L, Zaccaro D, O'Leary D, Howard G, Robbins D, Haffner S, and the Insulin Resistance Atherosclerosis Study Group. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. Stroke 28: 1710-1716, 1997.: I, T) Q1 j, D3 s8 K# c/ s, F
) ~4 H+ c6 _$ w% v* r3 k2 E$ H

6 u5 Q- W1 B" {3 k( p
Mykkanen L, Zaccaro D, Wagenknecht L, Robbins D, Gabriel M, and Haffner S. Microalbuminuria is associated with insulin resistance in nondiabetic subjects. The Insulin Resistance Atherosclerosis Study. Diabetes 47: 793-800, 1998./ Z4 P# E) O; p: S+ i2 w0 A
/ Y2 n& U; R3 T6 c/ h- S$ U) C

Nelson R, Meyer T, Meyers B, and Bennett P. Course of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Kidney Int 52, Suppl 63: S45-S48, 1997.- g, u6 k# Y* o+ ?$ ^

- Y5 D  Z) O$ a
Parving H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41: 745-759, 1998.

Parving H, Lehnert H, Rochner-Mortensen J, Gomis R, Andersen S, and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.

6 V# i1 R' n. p" E* |( `& W! M
Parving H, Oxenboll B, Svendsen P, Christiansen J, and Andersen A. Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol 100: 550-555, 1982.

. g, \- v! ?, A$ x: o; v5 N8 G* R
. w6 C& T7 X% v) t, ^
Pasceri V, Willerson J, and Yeh E. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.4 q. M' i0 G2 E2 {* n( @

3 a; H1 v* s, M* }6 n" h8 ~# v

Pepys M, Rowe I, and Baltz M. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 27: 83-111, 1982.7 w2 i9 B3 u: U( `

) Y/ r# n0 D% N% b% m* L4 B

Perkins B, Ficociello L, Silva K, Finkelstein D, Warram J, and Krolewski A. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348: 2285-2293, 2003.! l& W9 ?9 R) E8 M% d! d2 H
' [$ E" w$ u) X! M

! j2 C0 ^! r) j2 o. J( ~  u5 N5 ?  u
Potau N, Ibanez L, Tique S, and Carrascosa A. Pubertal changes in insulin secretion and peripheral insulin sensitivity. Horm Res 48: 219-226, 1997.4 b8 s" V6 z& @" r, ~+ y$ H
& G, J( i  z$ A
1 U% ?. d3 w3 C8 ^- X  i8 H
% P9 w) }. N& N  o
Ridker P, Cushman M, Stampfer M, Tracy R, and Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979, 1997.

2 ^2 D: X$ _9 w; k! V
; J( n. {* e  Q) S1 P+ ^3 M
Ridker P, Cushman M, Stapfer M, Tracy R, and Hennekens C. Plasma concentration of C-reactive protein and risks of developing peripheral vascular disease. Circulation 97: 425-428, 1998.# j5 t* R6 d- s( m" ?

" p. Z8 g% G9 o# f! Q1 M
! F( j  u; f( k
Ridker P, Glynn R, and Hennekens C. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97: 2007-2011, 1998.
4 G% a5 F( k* s( g, ~/ ~' a$ u
- N- B& v. A% l2 j  u2 R: U' C
" j) e% Q: @6 [. }
Ritz E. Nephropathy in type 2 diabetes. J Intern Med 245: 111-126, 1999.3 n( W7 e  B& i7 s( X; V2 G

Robbins D, Knowler W, Lee E, Yeh J, Go O, Welty T, Fabsitz R, and Howard B. Regional differences in albuminuria among American Indians: an epidemic of renal disease. Kidney Int 49: 557-563, 1996.+ Z2 q& Y( C" o7 v: v( W" Z/ Q
' z& |) l5 B* c# Z4 F7 W
" C  n% P+ R) Q0 ]
* |3 ]. ^% J# n& l  g- F" T# V
Roest M, Banga J, Janssen W, Grobbee D, Sixma J, Jong PD, Zeeuw DD, and van der Schouw YT. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103: 3057-3061, 2001.' O8 O0 k! X& u/ o# x

2 {# Z; f2 B6 O9 u0 ]& A+ F* P

Rosenbloom A, Joe J, Young R, and Winter W. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22: 345-354, 1999.1 w7 {$ r0 h# I6 x+ y

, R& v6 w' N# V& Z/ d. @
Rossing K, Jacobsen P, Pietraszek L, and Parving H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 26: 2268-2274, 2003.

6 {  O9 g2 ?; k' X' U
Sen A and Buyukgebiz A. Albumin excretion rate, serum insulin-like growth factor-I and glomerular filtration rate in type I diabetes mellitus at puberty. J Pediatr Endocrinol Metab 10: 209-215, 1997.
# C  {. X8 p# y- a$ }$ e5 F
, Z! L/ x" M0 K, B2 K
, T9 J* @9 q& K  T" ^0 d  X
Stehouwer C, Gall M, Twisk J, Knudsen E, Emeis J, and Parving H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51: 1157-1165, 2002.

) F$ e9 }, W- `: P4 _8 u
/ Y: `+ i7 C2 w# l
Stehouwer C, Nauta J, Zeldenrust G, Hackeng W, Donker A, and Ottolander G. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319-323, 1992./ A" ^6 ?3 n+ ~9 T& g3 [
9 b! S$ [" b& [' e& H( l: J( w5 T

0 }6 `0 k( U. o: X7 O
Stern M. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 44: 369-374, 1995.* h9 {/ o: y! k. ]

7 V1 |; @5 ?6 z$ P7 c! @
Stuveling E, Hillege H, Bakker S, Gans R, Jong PD, and Zeeuw DD. Creactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63: 654-661, 2003.
4 P$ R  ]6 i& \  Q4 ^: S6 G
( G" l: j7 N9 }5 ~# v

Svedberg J, Bjorntorp P, and Lonnroth P. Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 39: 570-574, 1990.5 F! Q. U/ @3 M; J0 a# K
5 ]: x# x1 q4 ]

Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, and Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 21: 116-120, 1988.
8 S/ M9 y5 w$ Q

% p. t2 R. s8 k
Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jarob W, and Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 51: 743-749, 2002.

: g/ z  ^' \/ o. Y

Torzewski J, Torzewski M, Bowyer D, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, and Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392, 1998.
3 z% s9 d  w. x! V& \

Tracy R, Lemaitre R, Psaty B, Ives D, Evans R, Cushman M, Meilahn E, and Kuller L. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17: 1121-1127, 1997.

3 \# T/ U: R# t- i; _5 ~! T
3 o0 s( T6 W0 `: _0 f. M4 [
Troiano R and Flegal K. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics 101: 497-504, 1998.( M* ^' _6 c. }# f" @% R& n5 o

6 d4 y! D( ?$ W3 s# T
Tucker B, Anderson C, Thies R, Collins R, and Blantz R. Glomerular hemodynamic alterations during acute hyperinsulinemia in normal and diabetic rats. Kidney Int 42: 1160-1168, 1992.
/ V! q9 ]* M. T8 B4 a
) i# C6 @2 n) T" ~! `$ Q

Tuttle K, Puhlman M, Cooney S, and Short R. Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis 34: 918-925, 1999.

8 k3 x5 I/ |1 ~$ \: t0 n) O
  c1 L+ R9 D% l! D
Tuttle K, Stein J, and DeFronzo R. The natural history of diabetic nephropathy. Semin Nephrol 10: 184-193, 1990.
! r9 O6 h" x' A
8 Z( M- f7 l4 Y2 N& j$ e  B7 Z4 ]
+ y6 \- g8 o: H# S9 n# D( c# }
United Kingdom Prospective Diabetes Study Group. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with type 2 diabetes. Lancet 352: 837-853, 1998.

0 o' {+ U3 Z" V" M

Valensi P, Assayag M, Busby M, and Attali JR. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 20: 574-579, 1996.  W1 L  @, O# L8 s
9 l. C3 [% A  r: h% ^

  A! w) `# R0 [8 E
Viberti G, Hill R, Jarrett R, Argyropoulos A, Mahmud U, and Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1: 1430-1432, 1982.
4 Y# ]$ _: Q2 v/ ]9 ^" ?8 p! N

Viberti G, Mogensen C, Groop L, Pauls J, and Group TEMCS. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275-279, 1994.% Q' K8 ^% g$ S3 n

  R' ^  |& I8 L5 U+ B

Winkler G, Lakatos P, Salamon F, Nagy Z, Speer G, Kovacs M, Harmos G, Dworak O, and Cseh K. Elevated serum TNF- level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 16: 207-211, 1999.
3 p! |# s* T; \; c
' m! l9 J( R) l( ^$ D5 h

Wolbink G, Brouwer M, Buysmann S, Berge IT, and Hack C. CRP mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 157: 473-479, 1996.

7 ^0 v! d8 p) F  z7 W' L1 r) T# V
Wu F and Eckardstein AV. Androgens and coronary artery disease. Endocr Rev 24: 183-217, 2003.$ b% c$ E+ N3 d
7 }$ g/ R' R2 p, K
) s0 y8 f& T, e8 n! v7 e3 A
2 q4 t- }; u9 Y. h* s
Yang W, Jeng C, Wu T, Tanaka S, Funahashi T, Matsuzawa Y, Chen JWC, Tai T, and Chuang L. Synthetic peroxisome proliferator-activated receptor- agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25: 376-380, 2002.! t5 E/ R2 t; X; q, e) E
& @- _0 D! b. E/ K0 i
; ~+ N. n6 o7 y  K
9 l  q" m7 ?  @, q4 f
Yudkin J, Forrest R, and Jackson C. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 2: 530-533, 1988.: s* g- `3 ?" ]0 l5 l; |5 x) m

/ A/ `1 ]' K- w$ x" i% T
Yudkin J, Kumari M, Humphries S, and Mohamed-Ali V. Inflammation, obesity, stress, and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000.7 }! G5 x' j% I- ]9 t
2 T0 j( i3 ~' L$ a. B$ R2 H% ]: m

Yudkin J, Stehouwer C, Emeis J, and Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978, 1999.# f" t) u, t. B, E  ?; k& b) I
. K7 V8 C' ?1 H% {; e0 h
* c; _' W" o3 g9 V
/ x7 S( D6 A. x! K
Zimmermann J, Herrlinger S, Pruy A, Metzger T, and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999.( Y3 d5 C3 i  E4 `* z9 d
. O3 T: x' L* e7 r& R* Y/ P& ?  D

; n) X2 O! Y) t* h" K
Zwaka T, Hombach V, and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197, 2001.

收藏0 分享0 顶0 踩0